JMP Securities initiated coverage of Structure Therapeutics with an Outperform rating and $90 price target. Structure is a clinical-stage biotech company focused on developing oral small molecule drugs to replace injectable biologics and peptides for chronic diseases, the analyst tells investors in a research note. The firm expects an effective, once-daily oral GLP-1R agonist “will be a compelling option for patients.” Structure’s lead asset GSBR-1290 is a fully-biased, small molecule, GLP-1R agonist, and biasing away from beta-arrestin signaling will confer efficacy and safety benefits, contends JMP.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GPCR:
- Structure Therapeutics management to meet with Piper Sandler
- Structure Therapeutics price target raised to $83 from $40 at BMO Capital
- Structure Therapeutics price target raised to $92 from $50 at Guggenheim
- Viking Therapeutics recent 50% selloff ‘excessive,’ says William Blair
- Structure Therapeutics price target raised to $97 from $46 at Leerink
